By Jack Choros
Canadian cannabis analytics company Strainprint Technologies launches groundbreaking medical cannabis patient retrospective report. The report summarizes key takeaways and results based on over 805,000 patient outcomes.
Who Benefits from the Report?
The report supports the medical cannabis ecosystem in the following ways:
● The report guides retailers and licensed producers to optimize their products and services to better meet customer needs.
● Clinicians and the broader medical community can gain a better understanding of patient behaviour and make better recommendations for treatment based on the data.
● The Consumer Packaged Goods industry can utilize the research in the development of new products.
● Financial institutions can gain a greater understanding of how products are being used in the market, which ultimately impact consumers both as medical cannabis users and banking customers.
● Governments and public health organizations can gain insights that will help create improved policies, guiding physicians and pharmacists.
The specific details of the report reveal several key insights. Perhaps the most striking is that many different cannabis species are offering patients comparable relief, meaning that the efficacy of a particular strain is based on more than just selected species or the THC-to-CBD ratio. What’s also interesting is that the data reveals the legalization of recreational cannabis use isn’t changing how or when patients treat their symptoms.
While there hasn’t been a change in that behaviour, patients are still overwhelmingly reporting either neutral or positive emotional effects from their medical cannabis use with very few reports of any negative experiences.
The preferred way to administer medical cannabis varies based on the age and geographic location of the patient while the most effective methods vary by both age and gender.
The report confirms that muscle and joint pain, anxiety, depression and insomnia are still the most common symptoms patients are treating using medical cannabis. Patients over 45 years of age are more likely to use it for joint pain while those under 45 are likely treating anxiety or muscle pain.
A free preview of The Canadian Medical Cannabis Experience: A 2019 Retrospective is available now, with the full report available for purchase at strainprint.ca/spt-reports/the-canadian-medical-cannabis-report/ .